Lilly to build $70M R&D facility in Indy

The 130,000-square foot facility, set to open in 2017, will be a center for research work on so called small molecule drugs that can be turned into pills as opposed to large molecule or protein-based drugs that are typically injected.

Read More

Lilly CEO: Drugmakers getting bum rap

Eli Lilly and Co. CEO John Lechleiter told Wall Street analysts recently that, while there have been “individual huge drug price increases,” the overall cost of drugs is rising very slowly and remains a small part of overall U.S. health care spending.

Read More